Encelta

Basel, Switzerland

Encelta T-cell therapy target and eliminate both blood cancers and solid tumors combined with bispecific antibodies.

$1.7M raised

May 2025

Grant

Top Investors

30,000+ verified contacts

Emails, phones & LinkedIn profiles

How much funding has Encelta raised?

Encelta has raised $1.7M in total funding. The most recent round was Grant. The last funding was announced in May 2025.

Who are Encelta's investors?

Encelta's investors include Innosuisse.

Where is Encelta headquartered?

Encelta is headquartered in Basel, Switzerland.

What does Encelta do?

Encelta T-cell therapy target and eliminate both blood cancers and solid tumors combined with bispecific antibodies.

What stage is Encelta at?

Encelta is at the Grant stage.

Cite this page

Free to use in articles, research, and reference works. Stable URL — will not change. Data on this page last updated May 19, 2025.

MLA

"Encelta — Funding & Investors." VCBacked, May 19, 2025, https://www.vcbacked.co/company/encelta. Accessed July 2, 2026.

APA

VCBacked. (2025). Encelta — Funding & Investors. Retrieved July 2, 2026, from https://www.vcbacked.co/company/encelta

Wikipedia (cite web)

{{cite web |title=Encelta — Funding & Investors |url=https://www.vcbacked.co/company/encelta |website=VCBacked |access-date=July 2, 2026}}

Profile data sourced and verified per the VCBacked methodology. Last funding round dated May 19, 2025.